rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2010-6-3-359-362rpcardio-879Research ArticleCLINICAL DISCUSSIONКЛИНИЧЕСКИЙ РАЗБОРSAFETY OF AMIODARONE USAGE IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME AND ATRIAL FIBRILLATIONК ВОПРОСУ О БЕЗОПАСНОСТИ ВВЕДЕНИЯ АМИОДАРОНА ПАЦИЕНТАМ С СИНДРОМОМ ВОЛЬФА-ПАРКИНСОНА-УАЙТА И ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙКужельД. А.KuzhelD. A.

к.м.н., доцент кафедры кардиологии и функциональной диагностики

зав. отделением функциональной диагностики

главный внештатный специалист по функциональной диагностике министерства здравоохранения администрации Красноярского края

660093, Красноярск, ул. Партизана Железняка, 1 

660097, Красноярск, ул. Карла Маркса, д. 43

Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022

Karla Marxa ul. 43, Krasnoyarsk, 660097 

ofdkkb2@4mail.ruМатюшинГ. В.MatyushinG. V.

д.м.н., профессор, зав. кафедрой кардиологии и функциональной диагностики

660093, Красноярск, ул. Партизана Железняка, 1 

Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022

СавченкоЕ. А.SavchenkoE. A.

к.м.н., доцент той же кафедры

660093, Красноярск, ул. Партизана Железняка, 1 

Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022

Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого, Красноярская краевая больница №2РоссияKrasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky, Krasnoyarsk Territory Hospital N2Russian FederationКрасноярский государственный медицинский университет им. проф. В.Ф. Войно-ЯсенецкогоРоссияKrasnoyarsk State Medical University named after Prof. V.F. Voyno-YasenetskyRussian Federation20101901201663359362Copyright © Kuzhel D.A., Matyushin G.V., Savchenko E.A., 20162016Кужель Д.А., Матюшин Г.В., Савченко Е.А.Kuzhel D.A., Matyushin G.V., Savchenko E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/879

Amiodarone is one of the basic antiarrhytmic drugs for atrial fibrillation treatment. However application of amiodarone in patients with atrial fibrillation and Wolff-Parkinson-White syndrome can induce ventricular fibrillation. Amiodarone usage in these patients should be accompanied by readiness for performance of resuscitation. This is confirmed by clinical case presentation.

Амиодарон считается одним из ведущих антиаритмических препаратов в лечении фибрилляции предсердий. Однако применение амиодарона у пациентов с фибилляцией предсердий и синдромом Вольфа-Паркинсона-Уайта может привести к развитию фибрилляции желудочков. Назначение амиодарона таким пациентам должно сопровождаться высокой степенью готовности к оказанию реанимационных мероприятий. Это подтверждает клинический случай, приведенный в статье.

амиодаронфибрилляция предсердийсиндром Вольфа-Паркинсона-Уайтафибрилляция желудочковamiodaroneatrial fibrillationWolff-Parkinson-White syndromeventricular fibrillationReferencesFuster V., Rydén L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114(7):e257-e354.Fuster V., Rydén L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114(7):e257-e354.Roden D.M. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 2000;84(3):339-46.Roden D.M. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 2000;84(3):339-46.Zimetbaum P. Amiodarone for Atrial Fibrillation. N Engl J Med 2007;356(9):935- 41.Zimetbaum P. Amiodarone for Atrial Fibrillation. N Engl J Med 2007;356(9):935- 41.Blomström-Lundqvist C., Scheinman M.M., Aliot E.M. et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/AmericanHeart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003;108(15):1871-909.Blomström-Lundqvist C., Scheinman M.M., Aliot E.M. et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/AmericanHeart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003;108(15):1871-909.Basson C.T. A molecular basis for Wolff–Parkinson–White syndrome. N EnglJ Med 2001;344(24):1861-4.Basson C.T. A molecular basis for Wolff–Parkinson–White syndrome. N EnglJ Med 2001;344(24):1861-4.Gollob M.H., Green M.S., Tang A.S-L. et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823-31.Gollob M.H., Green M.S., Tang A.S-L. et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823-31.Basavarajaiah S., Shah A., Sharma S. Sudden cardiac death in young athletes.Heart 2007;93(3):287-9.Basavarajaiah S., Shah A., Sharma S. Sudden cardiac death in young athletes.Heart 2007;93(3):287-9.Wren C. Sudden death in children and adolescents. Heart 2002;88(4):426-31.Wren C. Sudden death in children and adolescents. Heart 2002;88(4):426-31.Диагностика и лечение фибрилляции предсердий. Рекомендации комитета экспертов Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2005;4(4 Приложение 1):1-30.Диагностика и лечение фибрилляции предсердий. Рекомендации комитета экспертов Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2005;4(4 Приложение 1):1-30.Boriani G., Biffi M., Frabetti L. et al. Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Am Heart J 1996;131(6):1214-6.Boriani G., Biffi M., Frabetti L. et al. Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Am Heart J 1996;131(6):1214-6.Feld G.K., Nademanee K., Stevenson W. et al. Clinical and electrophysiologic effects of amiodarone in patients with atrialfibrillation complicating theWolff-Parkin￾son-White syndrome. Am Heart J 1988;115(1 Pt 1):102-7.Feld G.K., Nademanee K., Stevenson W. et al. Clinical and electrophysiologic effects of amiodarone in patients with atrialfibrillation complicating theWolff-Parkin￾son-White syndrome. Am Heart J 1988;115(1 Pt 1):102-7.Kappenberger L.J., Fromer M.A., Steinbrunn W., Shenasa M. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol 1984;54(3):330- 5.Kappenberger L.J., Fromer M.A., Steinbrunn W., Shenasa M. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol 1984;54(3):330- 5.Perticone F., Cuda G., Spadea F. et al. Malignant ventricular arrhythmia in the Wolff-Parkinson-White syndrome during amiodarone treatment. Clin Cardiol 1987;10(8):477-80.Perticone F., Cuda G., Spadea F. et al. Malignant ventricular arrhythmia in the Wolff-Parkinson-White syndrome during amiodarone treatment. Clin Cardiol 1987;10(8):477-80.Schützenberger W., Leisch F., Gmeiner R. Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report. Int J Cardiol 1987;16(1):93-5.Schützenberger W., Leisch F., Gmeiner R. Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation. A case report. Int J Cardiol 1987;16(1):93-5.Tijunelis M.A.,Herbert M.E. Myth: Intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency department. CJEM 2005;7(4):262-5.Tijunelis M.A.,Herbert M.E. Myth: Intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency department. CJEM 2005;7(4):262-5.Vitale P., De Stefano R., Auricchio A. Possible danger of rapid intravenous amiodarone in re-entry tachycardia in subjects with Wolff-Parkinson-White syndrome (in Italian). G Ital Cardiol 1986;16(11):969-74.Vitale P., De Stefano R., Auricchio A. Possible danger of rapid intravenous amiodarone in re-entry tachycardia in subjects with Wolff-Parkinson-White syndrome (in Italian). G Ital Cardiol 1986;16(11):969-74.

The authors declare that there are no conflicts of interest present.